Scientific deep-dive
Tirzepatide Versus Semaglutide on Mood
Across 80,000 matched pairs over two years, psychiatric outcomes were the same for both drugs. Against older GLP-1s, semaglutide was associated with half the rate of suicidal ideation.
People choosing between these two drugs often want to know whether one is harder on mood. A study of roughly 80,000 matched pairs followed for two years gives an unusually clean answer: no difference. The composite psychiatric outcome came out at 0.984 in year one and 1.002 in year two.[1]
The head-to-head
Hazard ratios that land on 0.98 and 1.00 across two years, in a sample that size, are about as close to a genuine null as observational data produces. Whatever separates these two drugs, psychiatric risk over two years does not appear to be it.[1]
The comparison that did show something
Against earlier-generation GLP-1 drugs rather than against tirzepatide, semaglutide looked different — and consistently so across every psychiatric outcome measured in year one.
| Outcome | Hazard ratio |
|---|---|
| Depression | 0.811 (95% CI 0.770–0.855) |
| Anxiety | 0.915 (95% CI 0.871–0.961) |
| Suicidal ideation | 0.488 (95% CI 0.339–0.702) |
| Composite psychiatric outcome | 0.866 (95% CI 0.832–0.901) |
The suicidal ideation figure is the one to sit with, given how much public argument this drug class has attracted on exactly that point. It halves, with an interval nowhere near one.
Where this sits with everything else
Three independent bodies of evidence now point the same way. A Swedish national cohort found semaglutide associated with lower risk of worsening mental illness and the class associated with less self-harm, which we covered in worsening mental illness. This study finds lower psychiatric event rates against older drugs in the class. And a randomized trial in major depressive disorder found no increase in suicidal ideation, covered here.
Pointing the other way is a spontaneous-reporting signal from FDA adverse event data, discussed in the FAERS analysis. That is the weakest design of the four, and the most susceptible to amplification by the news coverage this question generated.
Three matched cohorts and a randomized trial on one side. Voluntary reports on the other.
The same caution applies here as everywhere in this class: semaglutide reaching better outcomes than older drugs may reflect who receives the newest and most effective option rather than the molecule. That confound does not touch the tirzepatide comparison, though — both are current, both are prescribed to similar people, and the answer there was no difference.
Frequently Asked Questions
References
- 1.Chen SC, Wang TJ, Chou CK, et al. Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists Diabetes, Obesity and Metabolism. 2026. PMID: 42420795.
Compare the sellers
Related research
GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short
Semaglutide produced 13.88% weight loss against 0.42% on placebo in people taking clozapine, without altering clozapine levels or psychotic symptoms. The trial ended at 31 of an intended 80 because the drug ran out.
6 min read
GLP-1s and Worsening Mental Illness
Semaglutide was associated with 42% lower risk of worsening mental illness in people with depression and anxiety. Exenatide and dulaglutide showed nothing. Four drugs, one class, two very different results.
5 min read
Semaglutide and Motivation
Semaglutide reduced how heavily people with depression discounted effort, while leaving their sensitivity to probability unchanged. That dissociation is what makes the finding hard to dismiss.
5 min read
When the Primary Endpoint Fails and a Secondary Doesn't
A randomized trial in 72 people with major depressive disorder found no effect on executive function, its primary outcome. A secondary cognition measure cleared p=0.03, and that is the one that will be reported.
5 min read
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo, and by about the same amount whether or not the person had hypertension.
7 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
Where to get tirzepatide (Mounjaro / Zepbound) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
Knowing which pharmacy fills the vial: it names RedRock Pharmacy
From $129/mo
Get started →YourEra
Semaglutide at $99/month, 63% below the typical price
From $99/mo
Get started →Gala
Moving between compounded and brand without changing seller
From $149/mo
Get started →